NLTX Profile
Neoleukin Therapeutics Inc (NLTX) is a clinical-stage biopharmaceutical company developing immunotherapies based on de novo protein design. The company's proprietary technology platform, called de novo protein design, allows for the creation of novel proteins that can selectively bind to specific receptors on immune cells to either activate or inhibit the immune response. NLTX's lead candidate, NL-201, is a de novo protein designed to activate the interleukin-2 (IL-2) receptor complex, which is critical for the expansion and activation of T cells, a type of immune cell involved in fighting cancer and other diseases. NL-201 is currently in Phase 1 clinical trials for the treatment of advanced solid tumors and melanoma.
NLTX is also developing a pipeline of de novo protein therapeutics for the treatment of autoimmune and inflammatory diseases, including multiple sclerosis and inflammatory bowel disease. The company has partnerships with various pharmaceutical companies, including Eli Lilly and Company, for the development of its de novo protein therapeutics.
In addition to its clinical-stage programs, NLTX has also developed a discovery platform called "Atomwise," which uses artificial intelligence to screen small molecules for potential therapeutic activity. Atomwise has partnerships with several pharmaceutical companies, including Merck & Co. and Pfizer Inc., for the discovery of new small molecule drugs.
|
